834 related articles for article (PubMed ID: 23135914)
21. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC.
Williams R; Lee DW; Elzey BD; Anderson ME; Hostager BS; Lee JH
Head Neck; 2009 Jul; 31(7):911-8. PubMed ID: 19283850
[TBL] [Abstract][Full Text] [Related]
22. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
Muenst S; Hoeller S; Dirnhofer S; Tzankov A
Hum Pathol; 2009 Dec; 40(12):1715-22. PubMed ID: 19695683
[TBL] [Abstract][Full Text] [Related]
23. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications.
Chung CH; Gillison ML
Clin Cancer Res; 2009 Nov; 15(22):6758-62. PubMed ID: 19861444
[TBL] [Abstract][Full Text] [Related]
25. CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma.
Wagner S; Wittekindt C; Reuschenbach M; Hennig B; Thevarajah M; Würdemann N; Prigge ES; von Knebel Doeberitz M; Dreyer T; Gattenlöhner S; Klussmann JP
Int J Cancer; 2016 May; 138(9):2263-73. PubMed ID: 26662627
[TBL] [Abstract][Full Text] [Related]
26. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
Richendollar BG; Pohlman B; Elson P; Hsi ED
Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
[TBL] [Abstract][Full Text] [Related]
27. Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.
Badr M; Jöhrens K; Allgäuer M; Boxberg M; Weichert W; Tinhofer I; Denkert C; Schirmacher P; Stenzinger A; Budczies J
Cancer Immunol Immunother; 2019 Sep; 68(9):1443-1454. PubMed ID: 31444607
[TBL] [Abstract][Full Text] [Related]
28. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
29. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
30. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
[TBL] [Abstract][Full Text] [Related]
32. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood monocyte and T-lymphocyte activation levels at diagnosis predict long-term survival in head and neck squamous cell carcinoma patients.
Aarstad HJ; Vintermyr OK; Ulvestad E; Aarstad HH; Kross KW; Heimdal JH
APMIS; 2015 Apr; 123(4):305-14. PubMed ID: 25801083
[TBL] [Abstract][Full Text] [Related]
34. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
Lyford-Pike S; Peng S; Young GD; Taube JM; Westra WH; Akpeng B; Bruno TC; Richmon JD; Wang H; Bishop JA; Chen L; Drake CG; Topalian SL; Pardoll DM; Pai SI
Cancer Res; 2013 Mar; 73(6):1733-41. PubMed ID: 23288508
[TBL] [Abstract][Full Text] [Related]
35. The interplay between HPV and host immunity in head and neck squamous cell carcinoma.
Andersen AS; Koldjaer Sølling AS; Ovesen T; Rusan M
Int J Cancer; 2014 Jun; 134(12):2755-63. PubMed ID: 23913554
[TBL] [Abstract][Full Text] [Related]
36. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
Albers AE; Ferris RL; Kim GG; Chikamatsu K; DeLeo AB; Whiteside TL
Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774
[TBL] [Abstract][Full Text] [Related]
37. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma.
Takahashi H; Kawabata-Iwakawa R; Ida S; Mito I; Tada H; Chikamatsu K
Sci Rep; 2021 Sep; 11(1):17789. PubMed ID: 34493792
[TBL] [Abstract][Full Text] [Related]
38. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
39. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency.
Punt S; Dronkers EA; Welters MJ; Goedemans R; Koljenović S; Bloemena E; Snijders PJ; Gorter A; van der Burg SH; Baatenburg de Jong RJ; Jordanova ES
Cancer Immunol Immunother; 2016 Apr; 65(4):393-403. PubMed ID: 26899388
[TBL] [Abstract][Full Text] [Related]
40. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
Sewell DA; Douven D; Pan ZK; Rodriguez A; Paterson Y
Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):92-7. PubMed ID: 14732776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]